scholarly journals CLINICAL CHARACTERISTICS OF PATIENTS WITH SEASONAL ALLERGIC RHINOCONJUNCTIVITIS (SARK). ANAMNESTIC DATA AND THE STRUCTURE OF COMORBIDITY

2020 ◽  
pp. 72-81
Author(s):  
Олексій Кузнєцов
Keyword(s):  
Allergic Rhinitis ◽  
Infectious Diseases ◽  
Viral Hepatitis ◽  
Scarlet Fever ◽  
Seasonal Allergic Rhinitis ◽  
Acute Bronchitis ◽  
Control Group ◽  
Upper Respiratory Tract ◽  
Intestinal Infection ◽  
Nasal Symptoms

Introduction. Seasonal allergic rhinitis is AZ of mucous membranes (primarily the conjunctiva of the eye and nasal mucosa), due to hypersensitivity to aerosol allergens of plant pollen and fungi spores, the concentration of which in the air periodically becomes prijenosnog. The leading clinical manifestation of SAR is considered as allergic conjunctivitis. According to statistics, about 70-90% of patients with SAR develops Pulawy conjunctivitis, characterized by itching of eyes, eyelids, their redness, photophobia, lacrimation. Clinically important is the combination of SAR and conjunctivitis. Although the SAR attention usually emphasize on nasal symptoms, more than 80% of patients, as practice shows, suffer from symptoms from the eyes. According to the European and North American researchers, more than 70% of patients with SAR suffer from eye and nasal symptoms, and their severity the majority of patients assessed asmoderate or severe.Materials and methods. Clinical and anamnestic study was done in 120 patients aged from 19 to 45 years. All the studied patients were divided according to the degree of severity of the disease: 58 patients with moderate course of seasonal allergic rhinitis and conjunctivitis (EYE), which caused Pilica ambrosia and 62 patients with severe SARK, which pilca caused by ragweed. Of these, 43 (35,8%) women, 77 (64.1%) of men aged 19 to 25 years – 76 (63.3 per cent), from 25 to 45 years – 44 (36.6%) patients. The control group consisted of 30 healthy people.Research results. The differentiation of the history of infectious diseases patients. In the studied patients SARK with moderate current, acute respiratory illness (ARI) was observed in 54 (26,9%) patients, varicella – 16 (8,0%), mumps – 12 (6,0%), measles in 11 (5,5%), viral hepatitis in 4 (1,9%) patients, acute bronchitis 36 (17,9%), pneumonia – 17 (8,5%), the scarlet fever in 6 (2.9%) and intestinal infection in 7 (3,5%), sore throat – 25 (12,4%), otitis in 13 (6,5%) patients. In patients with severe SARK, ARI was observed in 59 (23,3%) patients, varicella – 24 (9,5%), mumps – in 18 (7.1 percent), measles – in 16 (6.3 percent), viral hepatitis in 7 (2.8%) and acute bronchitis – in 43 (17%), pneumonia in 19 (7,5%), scarlet fever in 8 (3,2%), intestinal infection in 9 (3,6%), angina 32 (12,6%), otitis media – in 18 (7.1 per cent) patients.Analyzing the structure of infectious diseases in the anamnesis in the studied patients SARK need to emphasize that their structure is dominated infection in the upper respiratory tract and broncho-pulmonary system that leads to depletion of nonspecific and specific immunity factors, formation of secondary immunodeficiency in these systems.Discussion of research. In the study of biochemical parameters of blood in patients with SARK in the period of aggravation established that the greatest changes are observed from endogenous cholesterol and phospholipids, which may indicate the failure of the macrophage link of immunity. At the same time, β-lipoproteins and NIK was increased only in the group of patients with severe SARK. The increase of phospholipids in serum of patients with severe SARK can point to the implementation of late phase allergic inflammation in cellular tissue structure of the nasal mucosa.Conclusions. Conducted research of history data, the structure of comorbidity, laboratory parameters allergological studies have shown that SARK is formed on the background of progressive sensitization and allergization of the organism, which is implemented in the manifestation of allergic reactions, forming the severity of SARK, and on the strength of the immune response to a variety of ecoalign that define the types of immunopathological reactions in this cohort of patients.

scholarly journals The immune system and the nature of immune disorders in patients with seasonal allergic rhinoconjunctivitis (sark) with moderate and severe

2020 ◽  
Keyword(s):  
Molecular Weight ◽  
Allergic Rhinitis ◽  
High Molecular Weight ◽  
Seasonal Allergic Rhinitis ◽  
Severe Disease ◽  
Specific Ige ◽  
Control Group ◽  
Low Molecular Weight ◽  
Nasal Symptoms ◽  
Group 2

Introduction. Seasonal allergic rhinitis is allergic diseases (AD) of mucous membranes (primarily the conjunctiva of the eye and nasal mucosa), due to hypersensitivity to aerosol allergens of plant pollen and fungi spores, the concentration of which in the air periodically becomes causal. The leading clinical manifestation of SAR is considered as allergic conjunctivitis. According to statistics, about 70–90 % of patients with SAR develops Pulawy conjunctivitis, characterized by itching of eyes, eyelids, their redness, photophobia, lacrimation. Clinically important is the combination of SAR and conjunctivitis. Although the SAR attention usually emphasize on nasal symptoms, more than 80 % of patients, as practice shows, suffer from symptoms from the eyes. According to the European and North American researchers, more than 70 % of patients with SAR suffer from eye and nasal symptoms, and their severity the majority of patients assessed as moderate or severe. Materials and methods. Were examined in 120 patients with seasonal allergic rhinitis in combination with conjunctivitis: 58 patients with moderate and 62 patients with severe disease. Research results. The patients of the 1st group the level of total IgE was increased 5.6 times, patients of group 2 – 7.1 times in comparison with the control group. The level of specific IgE in group 1 was 37.7 KU/L in group 2 – 46.9 KU/L, when reference levels – 0 – < 0,35 KU/L in the study, the CІC was established an increase of their concentration in patients of groups 1 and 2 groups. However, patients 1st group mainly increased levels of high molecular weight, the CІC, and in patients 2 groups – mainly the level of low molecular weight CІC. Discussion of research. The study of the population structure of the lymphatic peripheral blood of patients SARK revealed changes in T-cell link of immunity, characterized by a decrease in the content of CD3+-cells from patients 1 group by 10,7 %, in patients of group 2 – by 19,0 % in comparison with similar indicators of control group. Conclusions. Certain disorders in patients with severe disease are more profound than in patients with the moderate course of the disease. In patients with severe, in contrast to patients with moderate to severe flow disturbances and in the phagocytic link of immunity. In patients with severe as reduced the absorption activity of phagocytes and their ability in induction of reactive oxygen species. In patients with severe marked increase in the level of low molecular weight CІC, in patients with moderate to severe over – mainly high molecular weight of the CІC, which have less toxic than low molecular weight.

MP29-02 in the Treatment of Nasal Symptoms of Seasonal Allergic Rhinitis

2011 ◽  
Vol 127 (2) ◽  
pp. AB199-AB199
Author(s):  
W. Carr ◽  
S.R. Shah ◽  
W. Wheeler ◽  
H. Sacks
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Nasal Symptoms

Effects of topical budesonide and levocabastine on nasal symptoms and plasma exudation responses in seasonal allergic rhinitis

Allergy ◽  
1998 ◽  
Vol 53 (4) ◽  
pp. 367-374 ◽  
Author(s):  
C. Svensson ◽  
M. Andersson ◽  
L Greiff ◽  
L-O. Blychert ◽  
C. G. A. Persson
Keyword(s):  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Nasal Symptoms ◽  
Plasma Exudation

scholarly journals Evaluation of efficacy and safety of montelukast and levocetirizine FDC tablet compared to montelukast and levocetirizine tablet in patients with seasonal allergic rhinitis: a randomized, double blind, multicentre, phase III trial

2020 ◽  
Vol 7 (1) ◽  
pp. 83
Author(s):  
Sagar Panchal ◽  
Saiprasad Patil ◽  
Hanmant Barkate
Keyword(s):  
Quality Of Life ◽  
Allergic Rhinitis ◽  
Seasonal Allergic Rhinitis ◽  
Phase Iii ◽  
Fixed Dose ◽  
Controlled Study ◽  
Global Evaluation ◽  
Double Blind ◽  
Nasal Symptoms

<p class="abstract"><strong>Background:</strong> To evaluate efficacy, safety and tolerability of Montelukast 10 mg+levocetirizine 5 mg  FDC compared to either montelukast 10 mg or levocetirizine 5 mg given alone in seasonal allergic rhinitis (SAR) patients.</p><p class="abstract"><strong>Methods:</strong> Phase III, multicentre, randomized, double blind, parallel group, active controlled study was conducted in 279 SAR patients at 16 sites across India. Efficacy was assessed using daytime nasal symptoms score (Primary efficacy outcome), night-time symptoms score, daytime eye symptom score, patient's global evaluation, physician's global evaluation, rhino-conjunctivitis quality-of-life score.  </p><p class="abstract"><strong>Results:</strong> At end of treatment there was statistically significant evidence from the per protocol analysis that patients on FDC had a greater improvement in change from baseline in daytime nasal symptoms score than patients who received Montelukast (p=0.0266) or Levocetirizine (p=0.0409). These results were consistent with the Intent to treat analysis. Analysis of the secondary efficacy endpoints provided numerically greater improvement in the nighttime symptoms score, daytime eye symptoms score, and rhinoconjunctivitis quality-of-life scores in the FDC group as compared to the Montelukast group or Levocetirizine group. The FDC of Montelukast and Levocetirizine was found to be safe and generally well tolerated. The majority of adverse events were mild in severity, resolved without treatment and were unrelated to study medication.</p><p class="abstract"><strong>Conclusions:</strong> Fixed dose combination of Montelukast and Levocetirizine was safe, generally well tolerated and superior on efficacy compared to Montelukast or Levocetirizine in patients of seasonal allergic rhinitis.</p>

scholarly journals Comparison of Intranasal Hypertonic Dead Sea Saline Spray and Intranasal Aqueous Triamcinolone Spray in Seasonal Allergic Rhinitis

2005 ◽  
Vol 84 (7) ◽  
pp. 426-430 ◽  
Author(s):  
Scott Cordray ◽  
Jim B. Harjo ◽  
Linda Miner
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Mucosa ◽  
Seasonal Allergic Rhinitis ◽  
Dead Sea ◽  
Control Group ◽  
Life Questionnaire ◽  
Intranasal Corticosteroids ◽  
Eye Symptoms ◽  
The Dead ◽  
Positive Effect

Intranasal corticosteroids are well known to be efficacious in the treatment of allergic rhinitis. Nasal irrigation with saline, including hypertonic saline, has long been recommended for the treatment of sinonasal disease, and it has been shown to have a positive effect on the physiology of the nasal mucosa. Until now, no study of the clinical efficacy of intranasal hypertonic Dead Sea saline as a monotherapy for seasonal allergic rhinitis has been reported. We conducted a prospective, randomized, single-blind, placebo-controlled comparison of intranasal hypertonic Dead Sea saline spray and intranasal aqueous triamcinolone spray in 15 patients with seasonal allergic rhinitis. Results were based on a 7-day regimen. Based on Rhinoconjunctivitis Quality of Life Questionnaire scores, clinically and statistically significant (p < 0.0001) improvements were seen in both active-treatment groups; as expected, the corticosteroid spray was the more effective of the two treatments. No significant improvement occurred in the control group. Our preliminary results not only confirm the efficacy of intranasal corticosteroid therapy in moderate-to-severe allergic rhinitis, they also suggest that the Dead Sea saline solution can be an effective alternative in mild-to-moderate allergic rhinitis, particularly with respect to nasal and eye symptoms. The hypertonicity of the Dead Sea solution may have a positive effect on the physiology of the nasal mucosa by improving mucociliary clearance. In addition, the dominant cation in the Dead Sea solution— magnesium— probably exerts anti-inflammatory effects on the nasal mucosa and on the systemic immune response.

Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn)

2003 ◽  
Vol 91 (1) ◽  
pp. 44-48 ◽  
Author(s):  
Mark S. Dykewicz ◽  
Harold B. Kaiser ◽  
Robert A. Nathan ◽  
Stacey Goode-Sellers ◽  
Cindy K. Cook ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Fluticasone Propionate ◽  
Nasal Spray ◽  
Seasonal Allergic Rhinitis ◽  
Nasal Symptoms

Intranasal Mometasone Furoate for Treatment of Allergic Rhinitis

2010 ◽  
Vol 2 ◽  
pp. CMT.S4767 ◽  
Author(s):  
Marco Berlucchi ◽  
Barbara Pedruzzi
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Picture ◽  
Mometasone Furoate ◽  
Upper Respiratory Tract ◽  
Nasal Symptoms ◽  
Pharmacodynamic Profile ◽  
Nasal Disease ◽  
Oral Steroids ◽  
Adults And Children ◽  
Upper Respiratory

Allergic rhinitis (AR) is a chronic nasal disease that affects the upper respiratory tract. This disorder is characterized by inflammation of the mucous membranes and it manifests with several nasal symptoms accompanied sometimes by non-nasal symptoms. Best therapy aims to prevent and improve the AR-clinical picture. Steroids have an important role in the treatment of AR. The development of steroids administrated directly on nasal mucosa has much reduced the systemic adverse affects associated with oral steroids therapy. Mometasone furoate aqueous nasal spray is a synthetic steroid assessed for intranasal use in the therapy of adults and children affected by AR. Such topical nasal steroid is an effective molecule improving clinical picture of AR and it is also approved as prophylactic therapy. In this article, apart from a careful description of its successful clinical use the authors review pharmacokinetic/pharmacodynamic profile, mechanism of action, safety, and efficacy of such steroid molecule.

Sign in / Sign up

Export Citation Format

Share Document